Product Description
STSP-0902 is a recombinant human nerve growth factor fC fusion protein independently developed by Shu Taishen that targets specific sites. Preclinical experimental data shows that STSP-0902 can activate the TrkA receptor pathway, promote nerve growth, improve corneal integrity and corneal nerve length in rat neurotrophic keratitis models, and increase corneal sensory sensitivity. At the same time, compared with recombinant wild-type human nerve growth factor, STSP-0902 can also reduce the pain response caused by it. STSP-0902 was independently developed by the company, and invention patents have been applied for domestically and internationally. (Sourced from: https://www.moomoo.com/news/post/40504238/staidson-300204-sz-stsp-0902-eye-drops-obtained-a-new?level=1&data_ticket=1720730501154508)
Mechanisms of Action: NGF Modulator
Novel Mechanism: Yes
Modality: Coagulation Factor
Route of Administration: Subcutaneous,Ophthalmic
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Shutaishen (Beijing) Biopharmaceutical Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|